Other equities research analysts have also recently issued reports about the company. ValuEngine cut Xencor from a strong-buy rating to a buy rating in a research report on Saturday. Mizuho reaffirmed a buy rating on shares of Xencor in a research report on Tuesday, November 5th. Zacks Investment Research cut Xencor from a buy rating to a hold rating in a research report on Saturday, November 16th. Guggenheim initiated coverage on Xencor in a research report on Wednesday, November 20th. They set a hold rating on the stock. Finally, Leerink Swann dropped their price objective on Xencor from $52.00 to $44.00 and set an outperform rating on the stock in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $43.90.
Shares of NASDAQ:XNCR opened at $39.65 on Friday. Xencor has a 1-year low of $27.75 and a 1-year high of $46.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.92 and a quick ratio of 8.92. The business has a fifty day moving average price of $36.93 and a 200-day moving average price of $37.41. The company has a market capitalization of $2.31 billion, a PE ratio of -30.27 and a beta of 1.38.
Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.40. Xencor had a return on equity of 5.84% and a net margin of 21.60%. The firm had revenue of $21.76 million during the quarter, compared to the consensus estimate of $4.62 million. On average, sell-side analysts anticipate that Xencor will post 0.5 earnings per share for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC boosted its position in shares of Xencor by 76.3% during the third quarter. Barclays PLC now owns 54,143 shares of the biopharmaceutical company’s stock valued at $1,827,000 after buying an additional 23,439 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Xencor in the third quarter worth about $4,968,000. California State Teachers Retirement System boosted its position in Xencor by 1.2% in the third quarter. California State Teachers Retirement System now owns 73,722 shares of the biopharmaceutical company’s stock worth $2,487,000 after purchasing an additional 880 shares during the last quarter. EP Wealth Advisors LLC purchased a new position in Xencor in the third quarter worth about $1,091,000. Finally, State Street Corp boosted its position in Xencor by 58.8% in the third quarter. State Street Corp now owns 2,160,578 shares of the biopharmaceutical company’s stock worth $72,876,000 after purchasing an additional 799,664 shares during the last quarter. 92.43% of the stock is currently owned by institutional investors.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Read More: Preferred Stock
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.